Table 1.
Demographics and baseline characteristics: ITT population
| Parameter | Patients, n (%) | |
|---|---|---|
| Trastuzumab-dkst + taxane (N = 230) | Trastuzumab + taxane (N = 228) | |
| Age, mean (SD), years | 54.3 (11.0) | 52.9 (11.2) |
| Race, n (%) | ||
| Asian | 70 (30.4) | 72 (31.6) |
| Black or African American | 1 (0.4) | 2 (0.9) |
| White | 159 (69.1) | 154 (67.5) |
| Height, mean (SD), cm | 159.0 (7.1) | 159.3 (7.6) |
| Weight, mean (SD), kg | 68.4 (15.0) | 68.9 (16.0) |
| BSA, mean (SD), m2 | 1.73 (0.21) | 1.73 (0.22) |
| Assigned taxane, n (%) | ||
| Docetaxel | 193 (83.9) | 192 (84.2) |
| Paclitaxel | 35 (15.2) | 32 (14.0) |
| No treatment | 2 (0.9) | 4 (1.8) |
| ER + or PR + , n (%) | 102 (44.3) | 101 (44.3) |
| Prior treatment, n (%) | ||
| Trastuzumab | 22 (9.6) | 16 (7.0) |
| Taxane | 46 (20.0) | 42 (18.4) |
| Time from diagnosis to metastatic disease, n (%) | ||
| < 2 years | 146 (63.5) | 153 (67.1) |
| ≥ 2 years | 75 (32.6) | 71 (31.1) |
BSA body surface area, ER + estrogen receptor–positive, PR + progesterone receptor–positive